{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:15:43Z","timestamp":1793121343302,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00134-021-06431-0","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T04:11:09Z","timestamp":1622261469000},"page":"674-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial"],"prefix":"10.1007","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct03378479","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-1213","authenticated-orcid":false,"given":"Lore","family":"Vanderbeke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9629-8627","authenticated-orcid":false,"given":"Nico A. F.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-6426","authenticated-orcid":false,"given":"Dennis C. J. J.","family":"Bergmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-0778","authenticated-orcid":false,"given":"Jochem B.","family":"Buil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-8297","authenticated-orcid":false,"given":"Yves","family":"Debaveye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-5376","authenticated-orcid":false,"given":"Pieter","family":"Depuydt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7516-9471","authenticated-orcid":false,"given":"Simon","family":"Feys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-1500","authenticated-orcid":false,"given":"Greet","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Hoiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-4602","authenticated-orcid":false,"given":"Ben","family":"van der Hoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cato","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8668-1350","authenticated-orcid":false,"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1736-747X","authenticated-orcid":false,"given":"Virginie","family":"Lemiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9978-1414","authenticated-orcid":false,"given":"Piet","family":"Lormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-5980","authenticated-orcid":false,"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Meersseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2522-2764","authenticated-orcid":false,"given":"Bruno","family":"M\u00e9garbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-0357","authenticated-orcid":false,"given":"Saad","family":"Nseir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-9810","authenticated-orcid":false,"given":"Jos A. H.","family":"van Oers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-1279","authenticated-orcid":false,"given":"Marijke","family":"Reynders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3343-9610","authenticated-orcid":false,"given":"Bart J. A.","family":"Rijnders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9118-4420","authenticated-orcid":false,"given":"Jeroen A.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6342-0676","authenticated-orcid":false,"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-9072","authenticated-orcid":false,"given":"Karin","family":"Thevissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7798-6715","authenticated-orcid":false,"given":"Arnaud W.","family":"Thille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8353-2103","authenticated-orcid":false,"given":"Ruth","family":"Van Daele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1121-4894","authenticated-orcid":false,"given":"Frank L.","family":"van de Veerdonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-9860","authenticated-orcid":false,"given":"Paul E.","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4176-3608","authenticated-orcid":false,"given":"Alexander","family":"Wilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-725X","authenticated-orcid":false,"given":"Roger J. M.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-3897","authenticated-orcid":false,"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Dutch-Belgian Mycosis Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Rijnders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"van de Veerdonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schauwvlieghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Wolfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,29]]},"reference":[{"key":"6431_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1164\/rccm.201612-2540LE","volume":"196","author":"FL van de Veerdonk","year":"2017","unstructured":"van de Veerdonk FL, Kolwijck E, Lestrade PPA et al (2017) Influenza-associated aspergillosis in critically ill patients. Am J Respir Crit Care Med 196:524\u2013527. https:\/\/doi.org\/10.1164\/rccm.201612-2540LE","journal-title":"Am J Respir Crit Care Med"},{"key":"6431_CR2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","volume":"6","author":"AFAD Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe AFAD, Rijnders BJA, Philips N et al (2018) Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 6:782\u2013792. https:\/\/doi.org\/10.1016\/S2213-2600(18)30274-1","journal-title":"Lancet Respir Med"},{"key":"6431_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12890-020-01257-w","volume":"20","author":"L Chen","year":"2020","unstructured":"Chen L, Han X, Li Y et al (2020) Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study. BMC Pulm Med 20:239. https:\/\/doi.org\/10.1186\/s12890-020-01257-w","journal-title":"BMC Pulm Med"},{"key":"6431_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/J.JFMA.2017.06.002","volume":"116","author":"Y-H Ku","year":"2017","unstructured":"Ku Y-H, Chan K-S, Yang C-C et al (2017) Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections. J Formos Med Assoc 116:660\u2013670. https:\/\/doi.org\/10.1016\/J.JFMA.2017.06.002","journal-title":"J Formos Med Assoc"},{"key":"6431_CR5","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/cid\/ciaa007","volume":"71","author":"IS Schwartz","year":"2020","unstructured":"Schwartz IS, Friedman DZP, Zapernick L et al (2020) High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: a retrospective cohort study from alberta, canada. Clin Infect Dis 71:1760\u20131763. https:\/\/doi.org\/10.1093\/cid\/ciaa007","journal-title":"Clin Infect Dis"},{"key":"6431_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13054-020-2808-8","volume":"24","author":"K Thevissen","year":"2020","unstructured":"Thevissen K, Jacobs C, Holtappels M et al (2020) International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe. Crit Care 24:84. https:\/\/doi.org\/10.1186\/s13054-020-2808-8","journal-title":"Crit Care"},{"key":"6431_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1164\/rccm.201910-1931OC","volume":"202","author":"R Nyga","year":"2020","unstructured":"Nyga R, Maizel J, Nseir S et al (2020) Invasive tracheobronchial aspergillosis in critically ill patients with severe influenza a clinical trial. Am J Respir Crit Care Med 202:708\u2013716. https:\/\/doi.org\/10.1164\/rccm.201910-1931OC","journal-title":"Am J Respir Crit Care Med"},{"key":"6431_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/cid\/civ885","volume":"62","author":"PE Verweij","year":"2016","unstructured":"Verweij PE, Chowdhary A, Melchers WJG, Meis JF (2016) Azole resistance in aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis 62:362\u2013368. https:\/\/doi.org\/10.1093\/cid\/civ885","journal-title":"Clin Infect Dis"},{"key":"6431_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348\u2013359. https:\/\/doi.org\/10.1056\/NEJMoa061094","journal-title":"N Engl J Med"},{"key":"6431_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335\u2013347. https:\/\/doi.org\/10.1056\/NEJMoa061098","journal-title":"N Engl J Med"},{"issue":"Suppl I","key":"6431_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S et al (2018) Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 24(Suppl I):e1\u2013e38. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.002","journal-title":"Clin Microbiol Infect"},{"key":"6431_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","volume":"80","author":"L Chen","year":"2020","unstructured":"Chen L, Krekels EHJ, Verweij PE et al (2020) Pharmacokinetics and pharmacodynamics of posaconazole. Drugs 80:671\u2013695. https:\/\/doi.org\/10.1007\/s40265-020-01306-y","journal-title":"Drugs"},{"key":"6431_CR13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1128\/AAC.03850-14","volume":"59","author":"S Seyedmousavi","year":"2015","unstructured":"Seyedmousavi S, Mouton JW, Melchers WJG, Verweij PE (2015) Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis. Antimicrob Agents Chemother 59:1487\u20131494. https:\/\/doi.org\/10.1128\/AAC.03850-14","journal-title":"Antimicrob Agents Chemother"},{"key":"6431_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/myc.13028","volume":"63","author":"AFAD Schauwvlieghe","year":"2020","unstructured":"Schauwvlieghe AFAD, Buil JB, Verweij PE et al (2020) High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. Mycoses 63:122\u2013130. https:\/\/doi.org\/10.1111\/myc.13028","journal-title":"Mycoses"},{"key":"6431_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","volume":"397","author":"JA Maertens","year":"2021","unstructured":"Maertens JA, Rahav G, Lee DG et al (2021) Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet 397:499\u2013509. https:\/\/doi.org\/10.1016\/S0140-6736(21)00219-1","journal-title":"Lancet"},{"key":"6431_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1086\/341462","volume":"186","author":"JA McCullers","year":"2002","unstructured":"McCullers JA, Rehg JE (2002) Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 186:341\u2013350. https:\/\/doi.org\/10.1086\/341462","journal-title":"J Infect Dis"},{"key":"6431_CR17","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1128\/IAI.00298-15","volume":"83","author":"A Rynda-Apple","year":"2015","unstructured":"Rynda-Apple A, Robinson KM, Alcorn JF (2015) Influenza and bacterial superinfection: illuminating the immunologic mechanisms of disease. Infect Immun 83:3764\u20133770. https:\/\/doi.org\/10.1128\/IAI.00298-15","journal-title":"Infect Immun"},{"key":"6431_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3389\/fcimb.2017.00419","volume":"7","author":"LVN Oliveira","year":"2017","unstructured":"Oliveira LVN, Costa MC, Magalh\u00e3es TFF et al (2017) Influenza a virus as a predisposing factor for cryptococcosis. Front Cell Infect Microbiol 7:419. https:\/\/doi.org\/10.3389\/fcimb.2017.00419","journal-title":"Front Cell Infect Microbiol"},{"key":"6431_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.4049\/jimmunol.2000067","volume":"205","author":"JM Tobin","year":"2020","unstructured":"Tobin JM, Nickolich KL, Ramanan K et al (2020) Influenza suppresses neutrophil recruitment to the lung and exacerbates secondary invasive pulmonary aspergillosis. J Immunol 205:480\u2013488. https:\/\/doi.org\/10.4049\/jimmunol.2000067","journal-title":"J Immunol"},{"key":"6431_CR20","doi-asserted-by":"publisher","first-page":"e00242","DOI":"10.1128\/AAC.00242-18","volume":"62","author":"FB Sime","year":"2018","unstructured":"Sime FB, Stuart J, Butler J et al (2018) Pharmacokinetics of intravenous posaconazole in critically ill patients. Antimicrob Agents Chemother 62:e00242-e318. https:\/\/doi.org\/10.1128\/AAC.00242-18","journal-title":"Antimicrob Agents Chemother"},{"key":"6431_CR21","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/FTD.0b013e31821fb197","volume":"33","author":"J Ray","year":"2011","unstructured":"Ray J, Campbell L, Rudham S et al (2011) Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit 33:387\u2013392. https:\/\/doi.org\/10.1097\/FTD.0b013e31821fb197","journal-title":"Ther Drug Monit"},{"key":"6431_CR22","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2019","unstructured":"Donnelly JP, Chen SC, Kauffman CA et al (2019) Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis 71:1367\u20131376. https:\/\/doi.org\/10.1093\/cid\/ciz1008","journal-title":"Clin Infect Dis"},{"key":"6431_CR23","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","volume":"46","author":"PE Verweij","year":"2020","unstructured":"Verweij PE, Rijnders BJA, Br\u00fcggemann RJM et al (2020) Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 46:1524\u20131535. https:\/\/doi.org\/10.1007\/s00134-020-06091-6","journal-title":"Intensive Care Med."},{"key":"6431_CR24","unstructured":"EUCAST (2018) European Committee on antimicrobial susceptibility testing antifungal agents breakpoint tables for interpretation of MICs version 9.0. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/AFST\/Clinical_breakpoints\/Antifungal_breakpoints_v_9.0_180212.pdf. Accessed 30 Apr 2021"},{"key":"6431_CR25","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/cid\/ciaa010","volume":"71","author":"BJA Rijnders","year":"2020","unstructured":"Rijnders BJA, Schauwvlieghe AFAD, Wauters J (2020) Influenza-associated pulmonary aspergillosis: a local or global lethal combination? Clin Infect Dis 71:1764\u20131767. https:\/\/doi.org\/10.1093\/cid\/ciaa010","journal-title":"Clin Infect Dis"},{"key":"6431_CR26","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/s13054-020-03367-7","volume":"24","author":"T Mercier","year":"2020","unstructured":"Mercier T, Dunbar A, Veldhuizen V et al (2020) Point of care aspergillus testing in intensive care patients. Crit Care 24:642. https:\/\/doi.org\/10.1186\/s13054-020-03367-7","journal-title":"Crit Care"},{"key":"6431_CR27","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1128\/AAC.00233-15","volume":"59","author":"E Vermeulen","year":"2015","unstructured":"Vermeulen E, Maertens J, De Bel A et al (2015) Nationwide surveillance of azole resistance in aspergillus diseases. Antimicrob Agents Chemother 59:4569\u20134576. https:\/\/doi.org\/10.1128\/AAC.00233-15","journal-title":"Antimicrob Agents Chemother"},{"key":"6431_CR28","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3201\/eid2607.200088","volume":"26","author":"PPA Lestrade","year":"2020","unstructured":"Lestrade PPA, Buil JB, Van Der Beek MT et al (2020) Paradoxal trends in azole-resistant Aspergillus fumigatus in a national multicenter surveillance program, the Netherlands, 2013\u20132018. Emerg Infect Dis 26:1447\u20131455. https:\/\/doi.org\/10.3201\/eid2607.200088","journal-title":"Emerg Infect Dis"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-021-06431-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-021-06431-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-021-06431-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:14:18Z","timestamp":1744175658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-021-06431-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,29]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["6431"],"URL":"https:\/\/doi.org\/10.1007\/s00134-021-06431-0","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,29]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JBB reports grants from F2G, grants from Gilead Sciences, grants from Thermo Fisher Scientific, outside the submitted work. KL received consultancy fees from MSD, SMB Laboratoires Brussels and Gilead, non-financial support from Pfizer and MSD, received speaker fees from Gilead Sciences, FUJIFILM WAKO and Pfizer and a grant from Thermo Fisher Scientific. VL reports financial support of Pfizer, Fisher Paykel, Gilead Sciences, Alexion and Celgene to her research group, outside the submitted work. JM reports grants, personal fees and non-financial support from Gilead Sciences, MSD and Pfizer; personal fees and non-financial support from Cidara, F2G and Mundipharma; outside the submitted work. AWT reports personal fees and non-financial support from Fisher&Paykel, outside the submitted work. RVD reports non-financial support from Pfizer and Gilead Sciences, outside the submitted work. LV reports non-financial support from Gilead Sciences, outside the submitted work. PEV reports grants from Mundipharma, grants from F2G, grants from Pfizer, grants from Thermofisher, grants from Gilead Sciences, non-financial support from IMMY, grants from Cidara, outside the submitted work. RJMB reports consultancy fees from Mundipharma, Cidara, Amplyx, F2G, Gilead, Pfizer and MSD, speaker fees from Pfizer and Gilead, grants from Pfizer, Gilead and MSD. JW received speakers fee from MSD, Pfizer and Gilead, consultancy fee from Gilead and he obtained investigator-initiated grants from Gilead, Pfizer and MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All study procedures were performed in compliance with the principles of the Declaration of Helsinki, the principles of good clinical practice and in accordance with all applicable regulatory requirements. The study protocol was approved by the ethical committee of all participating centers in Belgium and France, and by the independent ethical committee Arnhem-Nijmegen for all 5 participating Dutch sites (CMO 2018-4041).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual patients or their legal representative.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}